Use of quantitative mass spectrometry-based proteomics and ELISA to compare the alpha 2 macroglobulin concentration in equine blood-based products processed by three different orthobiologic devices.
Authors: Ortved Kyla F, Alward Larry, Cowles Bobby, Linardi Renata, Barot Dhvani, Usimaki Alex, Fedie Joseph R, Amodie Deb, Goodrich Laurie R
Journal: Frontiers in veterinary science
Summary
# Editorial Summary: Alpha 2 Macroglobulin Concentration Across Equine Orthobiologic Devices Alpha 2 macroglobulin (A2M) is a key plasma protein that suppresses inflammatory cytokines and neutralises cartilage-degrading enzymes—making it a particularly valuable component of treatments for joint disease and osteoarthritis in horses. Ortved and colleagues used mass spectrometry-based proteomics alongside traditional ELISA methods to measure A2M concentrations in blood-derived products prepared by three different stall-side orthobiologic devices, providing a direct comparison of processing efficiency that hasn't previously been documented. Results varied substantially between devices, with specific A2M yields differing based on the preparation technology employed, though the authors' full quantitative findings warrant review of the published data for your particular clinical context. For practitioners selecting between commercial systems, these findings suggest that device choice genuinely influences the final A2M concentration delivered to the joint—a critical consideration given that A2M's anti-inflammatory and protease-inhibiting properties underpin much of the theoretical benefit in regenerative therapy. Understanding these differences allows farriers, veterinarians and physiotherapists to make more informed decisions about which platform may optimise therapeutic outcomes for individual cases.
Read the full abstract on PubMed
Practical Takeaways
- •Device selection for stall-side regenerative therapy may impact the concentration of therapeutic proteins like A2M delivered to the joint
- •A2M quantification using standardized analytical methods provides objective comparison of orthobiologic product quality across different processing devices
- •Understanding differences in A2M concentration between devices can help practitioners select treatments with potentially superior anti-inflammatory and enzyme-clearing properties
Key Findings
- •Alpha 2 macroglobulin (A2M) concentrations were compared across three commercial orthobiologic devices using quantitative mass spectrometry and ELISA methods
- •A2M is a multi-functional plasma protease inhibitor that regulates proinflammatory cytokines and clears chondrodestructive enzymes in joint disease
- •Study validated both mass spectrometry-based proteomics and ELISA as analytical methods for measuring A2M in equine blood-based products